Biologic Medicines in Dermatology      

FOI REFERENCE: 24356 FOI DATE: 10th September 2024   

     

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira – *
• Adalimumab Biosimilar – 68
• Apremilast – *
• Bimekizumab – *
• Brodalumab – 5
• Certolizumab – *
• Deucravacitinib – 0
• Dimethyl fumarate – 0
• Etanercept – Enbrel – *
• Etanercept Biosimilar – 0
• Guselkumab – 0
• Infliximab – Remicade – 0
• Infliximab Biosimilar – 0
• Ixekizumab – *
• Risankizumab – 5
• Secukinumab – 25
• Tildrakizumab – 0
• Ustekinumab – 28
• Ustekinumab Biosimilar – 0
• Omalizumab – 0

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

• Adalimumab – Humira – *
• Adalimumab Biosimilar – 5
• Bimekizumab – 0
• Certolizumab – 0
• Infliximab – Remicade – 0         
• Infliximab Biosimilar – 0
• Secukinumab – 0
• Ustekinumab – 0
• Ustekinumab Biosimilar – 0